Newsroom | 44642 results

SAN FRANCISCO--(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK), a common age-related condition resulting in precancerous skin lesions, that is most commonly seen after age 65.1 The open-label multi-center trial, conducted in the United States, assessed the safety, to...

BOSTON--(BUSINESS WIRE)--Ontada will present a real-world research study at the ASCO Annual Meeting examining GLP-1 receptor agonist utilization and overall survival outcomes....

SAN FRANCISCO--(BUSINESS WIRE)--ŌURA, maker of the world’s leading smart ring, today announced Oura Ring 5, the smallest smart ring in the world. Built on more than twelve years of industry-leading innovation, Oura delivers its most advanced health sensing and insights in a more comfortable and compact form than ever before. Crafted from lightweight, non-allergenic titanium, Oura Ring 5 goes beyond tracking. Oura pairs its most innovative hardware yet with new software that moves beyond trackin...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND)(“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update. Krishna Gupta, Chairman of Vyome, said, “Over the last several quarters, Vyome has executed with focus and discipline, advancing differentiated programs in areas of significant unmet medical need focused on...

NEW YORK--(BUSINESS WIRE)--Magic Molecule, one of the leading hypochlorous acid skincare brands, today announced that its FDA-cleared Daily Skin Spray will become the first hypochlorous acid solution sold in the health and beauty aids department at Sprouts Farmers Market. Used in clinical settings for decades, hypochlorous acid is a molecule that is naturally produced by white blood cells to defend against bacteria and promote healing. Magic Molecule’s Daily Skin Spray is produced in Magic Scie...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside ch...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma announces patent applications and preclinical data supporting investigational intranasal and pulmonary GLP-1 delivery....

東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- 3D Investment Partners Pte. Ltd.が投資一任運用サービスを提供するファンド（以下、3D Investment Partners Pte. Ltd.と当該ファンドとを併せて「3D」）は、2020年7月に東邦ホールディングス株式会社（東証：8129、以下「東邦HD」又は「同社」）に投資を開始して以来、継続して同社の株式を保有し、現在、約24%の議決権を有する東邦HDの株主です。 3Dは、本日、2026年6月26日に開催予定の第78回定時株主総会にて東邦HDが上程する、買収防衛策の発動是非を株主の皆様にはかる議案（第4号議案「新株予約権無償割当ての件」、以下「本買収防衛策発動議案」）に対し、株主の皆様に賢明なご判断を呼びかけるプレゼンテーション資料を公表しました。 本プレゼン資料：https://www.3dipartners.com/engagement/toho-presentation-material-jp-202605.pdf あわせて、これまでの全開示資料をまとめた特設サイト、及び...

PITTSBURGH--(BUSINESS WIRE)--Life Science Connect ( “LSC”) is pleased to announce the appointment of Tony Cannon as its Chief Financial Officer. LSC welcomes Mr. Cannon to the team at a pivotal moment as the Company continues to strengthen its financial infrastructure and capabilities to support its continued growth. LSC is a portfolio company of Latticework Capital Management and Edgehill Management. LSC, headquartered in Pittsburgh, Pennsylvania, operates a network of trusted editorial commun...

FRANKFURT, Germany & RALEIGH, N.C.--(BUSINESS WIRE)--Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new research at the World Parkinson Congress (WPC) 2026 that uncovers the multifaceted burden of "OFF" episodes in Parkinson's disease (PD). The qualitative literature review demonstrates that these episodes are not only a re-emergence of motor symptoms, but also a complex mix of debilitating motor and non-motor symptoms that impact...